Biodesix (NASDAQ:BDSX) is a precision diagnostics company focused on developing and commercializing blood-based tests for lung cancer and other serious diseases. Headquartered in Boulder, Colorado, the company leverages proteomics, bioinformatics and machine learning to identify and validate molecular signatures that aid in diagnosis, prognosis and therapeutic selection. Since its founding in 2005, Biodesix has sought to address unmet needs in oncology by providing clinicians with noninvasive tests that complement traditional imaging and tissue biopsy methods.
The company’s portfolio includes commercially available tests such as VeriStrat®, which predicts response to certain therapies in non-small cell lung cancer, and Nodify™ Lung, designed to assess the malignancy risk of pulmonary nodules. Biodesix continues to expand its test menu through internal research and strategic collaborations, focusing on applications in immuno-oncology, targeted therapy selection and disease monitoring. In parallel, the firm invests in biomarker discovery efforts to support companion diagnostic development for pharmaceutical partners.
Biodesix operates a CLIA-certified laboratory in Boulder and serves a broad network of oncology clinics, academic medical centers and reference laboratories across the United States. The company’s tests have been incorporated into clinical workflows and guidelines, reflecting its commitment to rigorous analytical validation and clinical evidence generation. Biodesix also pursues regulatory clearances and engages with payers to facilitate reimbursement for its assays, aiming to broaden patient access and drive adoption.
Under the leadership of President and Chief Executive Officer Brian R. Nadler, Biodesix maintains a management team with deep expertise in diagnostics, life sciences and commercial strategy. The company’s board and scientific advisory committee include industry veterans and academic researchers who guide its innovation roadmap. Looking ahead, Biodesix is poised to advance its pipeline of proteomic tests and strengthen partnerships that support personalized medicine in oncology and beyond.
